{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:01:52Z","timestamp":1793278912798,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteoclasts (OCs) are large multinucleated cells derived from progenitor cells of the monocyte-macrophage lineage. Signal transduction via the macrophage\u2013colony-stimulating factor (M-CSF) receptor, c-fms, is essential for OC formation. Since we have previously demonstrated inhibition of c-fms by imatinib, we examined the effect of imatinib on OC formation and activity. OC formation was not affected by concentrations of 1.0 \u03bcM imatinib and lower, but was reduced by 75% at 3.0 \u03bcM imatinib. In contrast, both the area of resorption and the number of resorption lacunae were reduced by 80% at 0.3 \u03bcM imatinib, and no resorption was observed at concentrations above 3.0 \u03bcM. A dose-dependent decrease in receptor activator of nuclear factor \u03baB (RANK) expression was observed in OCs when cultured in the presence of imatinib, providing a mechanism for the decrease in OC function. In vivo analysis of the effect of imatinib on OC activity in adult mice following 8 weeks of imatinib treatment also demonstrated a decrease in OC activity. These results suggest that imatinib may have therapeutic value as an antiosteolytic agent in diseases such as osteoporosis, metastatic bone disease, and multiple myeloma.<\/jats:p>","DOI":"10.1182\/blood-2005-09-3568","type":"journal-article","created":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T04:07:51Z","timestamp":1138766871000},"page":"4334-4337","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Imatinib as a potential antiresorptive therapy for bone disease"],"prefix":"10.1182","volume":"107","author":[{"given":"Andrea L.","family":"Dewar","sequence":"first","affiliation":[{"name":"From the Myeloma and Mesenchymal Research Laboratory, the Division of Haematology, Level 2 Hanson Institute, and the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science (IMVS), Adelaide, South Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Farrugia","sequence":"additional","affiliation":[{"name":"From the Myeloma and Mesenchymal Research Laboratory, the Division of Haematology, Level 2 Hanson Institute, and the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science (IMVS), Adelaide, South Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Condina","sequence":"additional","affiliation":[{"name":"From the Myeloma and Mesenchymal Research Laboratory, the Division of Haematology, Level 2 Hanson Institute, and the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science (IMVS), Adelaide, South Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bik To","sequence":"additional","affiliation":[{"name":"From the Myeloma and Mesenchymal Research Laboratory, the Division of Haematology, Level 2 Hanson Institute, and the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science (IMVS), Adelaide, South Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"From the Myeloma and Mesenchymal Research Laboratory, the Division of Haematology, Level 2 Hanson Institute, and the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science (IMVS), Adelaide, South Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrie","family":"Vernon-Roberts","sequence":"additional","affiliation":[{"name":"From the Myeloma and Mesenchymal Research Laboratory, the Division of Haematology, Level 2 Hanson Institute, and the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science (IMVS), Adelaide, South Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C. W.","family":"Zannettino","sequence":"additional","affiliation":[{"name":"From the Myeloma and Mesenchymal Research Laboratory, the Division of Haematology, Level 2 Hanson Institute, and the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science (IMVS), Adelaide, South Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111711363548000_REF1","doi-asserted-by":"crossref","unstructured":"Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 1996;137: 4058-4060.","DOI":"10.1210\/endo.137.9.8756585"},{"key":"2019111711363548000_REF2","unstructured":"Mundy GR. Bone Remodeling and Its Disorders. London, England: Martin Dunitz Ltd; 1995."},{"key":"2019111711363548000_REF3","doi-asserted-by":"crossref","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2: 584-593.","DOI":"10.1038\/nrc867"},{"key":"2019111711363548000_REF4","doi-asserted-by":"crossref","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2: 561-566.","DOI":"10.1038\/nm0596-561"},{"key":"2019111711363548000_REF5","doi-asserted-by":"crossref","unstructured":"Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39: 2006-2011.","DOI":"10.1016\/S0959-8049(02)00836-5"},{"key":"2019111711363548000_REF6","doi-asserted-by":"crossref","unstructured":"Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005; 105: 3127-3132.","DOI":"10.1182\/blood-2004-10-3967"},{"key":"2019111711363548000_REF7","doi-asserted-by":"crossref","unstructured":"Tanaka H, Matsumura I, Nakajima K, et al. GATA-1 blocks IL-6-induced macrophage differentiation and apoptosis through the sustained expression of cyclin D1 and bcl-2 in a murine myeloid cell line M1. Blood. 2000;95: 1264-1273.","DOI":"10.1182\/blood.V95.4.1264.004k09_1264_1273"},{"key":"2019111711363548000_REF8","doi-asserted-by":"crossref","unstructured":"Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol. 2005;83: 48-56.","DOI":"10.1111\/j.1440-1711.2004.01296.x"},{"key":"2019111711363548000_REF9","doi-asserted-by":"crossref","unstructured":"Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005;65: 1700-1709.","DOI":"10.1158\/0008-5472.CAN-04-1687"},{"key":"2019111711363548000_REF10","doi-asserted-by":"crossref","unstructured":"Wolff NC, Ilaria RL Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 2001;98: 2808-2816.","DOI":"10.1182\/blood.V98.9.2808"},{"key":"2019111711363548000_REF11","doi-asserted-by":"crossref","unstructured":"Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998;188: 997-1001.","DOI":"10.1084\/jem.188.5.997"},{"key":"2019111711363548000_REF12","doi-asserted-by":"crossref","unstructured":"Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A. 1998;95: 3597-3602.","DOI":"10.1073\/pnas.95.7.3597"},{"key":"2019111711363548000_REF13","doi-asserted-by":"crossref","unstructured":"Nicholson GC, Malakellis M, Collier FM, et al. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin Sci (Lond). 2000;99: 133-140.","DOI":"10.1042\/cs0990133"},{"key":"2019111711363548000_REF14","doi-asserted-by":"crossref","unstructured":"Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med. 1999;190: 1741-1754.","DOI":"10.1084\/jem.190.12.1741"},{"key":"2019111711363548000_REF15","doi-asserted-by":"crossref","unstructured":"Severson AR. Differentiation of mononuclear cells into multinucleated osteoclast-like cells. Exp Cell Biol. 1983;51: 267-274.","DOI":"10.1159\/000163202"},{"key":"2019111711363548000_REF16","doi-asserted-by":"crossref","unstructured":"Marks SC Jr, Lane PW. Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. J Hered. 1976;67: 11-18.","DOI":"10.1093\/oxfordjournals.jhered.a108657"},{"key":"2019111711363548000_REF17","doi-asserted-by":"crossref","unstructured":"Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op\/op) mouse. Proc Natl Acad Sci U S A. 1990; 87: 4828-4832.","DOI":"10.1073\/pnas.87.12.4828"},{"key":"2019111711363548000_REF18","doi-asserted-by":"crossref","unstructured":"Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest. 1993;91: 257-263.","DOI":"10.1172\/JCI116179"},{"key":"2019111711363548000_REF19","doi-asserted-by":"crossref","unstructured":"Amano H, Yamada S, Felix R. Colony-stimulating factor-1 stimulates the fusion process in osteoclasts. J Bone Miner Res. 1998;13: 846-853.","DOI":"10.1359\/jbmr.1998.13.5.846"},{"key":"2019111711363548000_REF20","doi-asserted-by":"crossref","unstructured":"Begg SK, Radley JM, Pollard JW, et al. Delayed hematopoietic development in osteopetrotic (op\/op) mice. J Exp Med. 1993;177: 237-242.","DOI":"10.1084\/jem.177.1.237"},{"key":"2019111711363548000_REF21","doi-asserted-by":"crossref","unstructured":"Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony stimulating factor in the support of osteoclastic bone resorption. J Exp Med. 1999; 190: 293-298.","DOI":"10.1084\/jem.190.2.293"},{"key":"2019111711363548000_REF22","doi-asserted-by":"crossref","unstructured":"Niida S, Kondo T, Hiratsuka S, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A. 2005;102: 14016-14021.","DOI":"10.1073\/pnas.0503544102"},{"key":"2019111711363548000_REF23","doi-asserted-by":"crossref","unstructured":"Wolber FM, Leonard E, Michael S, et al. Roles of spleen and liver in development of the murine hematopoietic system. Exp Hematol. 2002;30: 1010-1019.","DOI":"10.1016\/S0301-472X(02)00881-0"},{"key":"2019111711363548000_REF24","doi-asserted-by":"crossref","unstructured":"Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood. 2004;104: 495-501.","DOI":"10.1182\/blood-2003-08-2695"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/11\/4334\/1278787\/zh801106004334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/11\/4334\/1278787\/zh801106004334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T16:36:40Z","timestamp":1574008600000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/11\/4334\/21987\/Imatinib-as-a-potential-antiresorptive-therapy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-09-3568","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}